You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TeliMET NSCLC-01

Showing 1 - 25 of 4,827
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, NSCLC, Lung Cancer Trial in Port Saint Lucie, Greenville (BL-B01D1)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Port Saint Lucie, Florida
  • +1 more
Aug 11, 2023

NSCLC Trial (Atezolizumab, Tiragolumab)

Not yet recruiting
  • NSCLC
  • (no location specified)
Apr 5, 2023

NSCLC Trial (KB-GDT-01)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • KB-GDT-01
  • (no location specified)
Sep 29, 2023

Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • No intervention
  • Bydgoszcz, Poland
  • +11 more
Feb 22, 2023

Stage IV NSCLC Trial in Czechia, Slovakia (DCVAC add on to SOC, DCVAC and immune enhancers add on to SOC, Standard of Care

Completed
  • Stage IV Non-small Cell Lung Cancer
  • DCVAC add on to SOC
  • +2 more
  • Brno, Czechia
  • +17 more
May 3, 2022

Melanoma (Skin), Non-Small-Cell Lung Carcinoma Trial in Belgium, Spain, United Kingdom (GAd-PEV, MVA-PEV)

Recruiting
  • Melanoma (Skin)
  • Non-Small-Cell Lung Carcinoma
  • GAd-PEV
  • MVA-PEV
  • Charleroi, Belgium
  • +6 more
Feb 23, 2022

Non-Squamous NSCLC (NSCLC), Adenocarcinoma of the Lung, Lung Cancer Trial in United States (Docetaxel, Nivolumab, Gemcitabine)

Terminated
Has Results
  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • +3 more
  • Anderson, Indiana
  • +8 more
Jul 7, 2022

Non Small Cell Lung Cancer Trial in Worldwide (Telisotuzumab Vedotin, Docetaxel)

Recruiting
  • Non Small Cell Lung Cancer
  • Los Angeles, California
  • +212 more
Jan 26, 2023

Oncology, Melanoma, Ovarian Cancer Trial in United States (E-602, Pembrolizumab)

Recruiting
  • Oncology
  • +16 more
  • E-602
  • Pembrolizumab
  • Grand Rapids, Michigan
  • +4 more
May 27, 2022

NSCLC Trial in Netherlands (Durvalumab, low-dose PCI)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Almelo, Netherlands
  • +11 more
Feb 1, 2022

NSCLC, Recurrent, Adenocarcinoma of Lung Trial (Vargatef, Abraxane, )

Withdrawn
  • NSCLC, Recurrent
  • Adenocarcinoma of Lung
  • (no location specified)
Nov 20, 2020

NSCLC Trial in China (JAB 21822)

Recruiting
  • Non-small Cell Lung Cancer
  • JAB 21822
  • Beijing, Beijing, China
  • +20 more
Sep 26, 2022

Melanoma, Renal Cell Carcinoma, NSCLC Trial in United States (HBI-8000 in combination with nivolumab)

Active, not recruiting
  • Melanoma
  • +2 more
  • HBI-8000 in combination with nivolumab
  • Phoenix, Arizona
  • +5 more
Jun 11, 2022

NSCLC Trial in Belgium, France, United States (Cisplatin, Carboplatin, Pemetrexed)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • Fountain Valley, California
  • +18 more
Aug 10, 2022

Resectable Early-stage Non-small Cell Lung Cancer

Completed
  • Non-small Cell Lung Cancer
    • Alexandria, Egypt
    • +3 more
    Nov 21, 2022

    ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

    Active, not recruiting
    Has Results
    • ALK-positive Advanced NSCLC
    • Orange, California
    • +79 more
    Nov 15, 2022

    NSCLC Trial in Shanghai (Injection of 99m-Tc-NM-01)

    Unknown status
    • Non-Small Cell Lung Cancer
    • Injection of 99m-Tc-NM-01
    • Shanghai, China
    • +1 more
    Aug 20, 2020

    NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Telisotuzumab Vedotin
    • +4 more
    • (no location specified)
    Oct 17, 2023

    NSCLC Trial in Worldwide (Entrectinib, Crizotinib)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Barretos, SP, Brazil
    • +66 more
    Jan 27, 2023

    Non Small Cell Lung Carcinoma NSCLC Trial in Worldwide (Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine +

    Active, not recruiting
    Has Results
    • Non Small Cell Lung Carcinoma NSCLC
    • Durvalumab +Tremelimumab
    • +5 more
    • Anaheim, California
    • +210 more
    Jan 4, 2023

    Clinical Implications for NSCLC Patients With Rare Mutations

    Recruiting
    • NSCLC
    • +2 more
      • Shanghai, Shanghai, China
      • +1 more
      Jan 18, 2023

      Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

      Recruiting
      • Non-small Cell Lung Cancer
        • Guanzhou, China
          Sun Yat-sen University Cancer Center
        Aug 11, 2023

        Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

        Not yet recruiting
        • Pancreatic Ductal Adenocarcinoma
        • +4 more
        • (no location specified)
        Oct 23, 2023

        Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Orange,

        Not yet recruiting
        • Metastatic Lung Non-Small Cell Carcinoma
        • +8 more
        • Orange, California
        • +2 more
        Aug 10, 2022

        NSCLC, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma Trial in Duarte (Autologous, engineered T Cells targeting

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • +5 more
        • Autologous, engineered T Cells targeting TP53 R175H
        • Duarte, California
          City of Hope
        May 17, 2023